BCRX


3 Biotech Stocks Under $4 With Big Upside Potential

At the very moment it looked like the market was down for the count, stocks bounced back. After being dealt hefty blows earlier in the week due to …

Here’s Why BioCryst Pharmaceuticals, Inc. (BCRX) Shares Popped Today

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) investors cheer the news that the FDA has approved the supplemental New Drug Application (sNDA) to expand the indication …

Here’s Why BioCryst Pharmaceuticals, Inc. (BCRX) Skyrocket Today

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) investors have a smile on their faces Thursday morning, after the drug maker announced results from a second interim …

H.C. Wainwright Maintains Buy On BioCryst Pharmaceuticals, Inc. (BCRX) Following 1Q:16 Update

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares slipped yesterday 9% after the drug discovery company reported first-quarter results and update on its clinical progress.

The Ups and Downs of Biotech: Cerus Corporation (CERS) and BioCryst Pharmaceuticals, Inc. (BCRX)

The volatile biotech sector did not fail to live up to its reputation this week. Analysts weigh in on Cerus Corporation (NASDAQ:CERS) as …

Biotech Beat: Oppenheimer Analysts Weigh In on Sarepta Therapeutics, Inc. (SRPT) and BioCryst Pharmaceuticals (BCRX)

Oppenheimer analysts express mixed sentiments on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) and BioCryst Pharmaceuticals (NASDAQ:BCRX) as one company awaits an extended review from the FDA …

Piper Jaffray Weighs In on Two Collapsing Biotechs: CTI BioPharma Corp (CTIC), BioCryst Pharmaceuticals, Inc. (BCRX)

Piper Jaffray’s healthcare analyst Charles Duncan is weighing in today on biotech companies CTI BioPharma Corp (NASDAQ:CTIC) and BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), as shares …

Stock Update (NASDAQ:BCRX): BioCryst Pharmaceuticals, Inc. Announces Clinical Results in Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced results from OPuS-2 (Oral ProphylaxiS-2), a clinical trial of avoralstat administered three times daily as a liquid-filled soft …

Company Update (NASDAQ:BCRX): BioCryst Pharmaceuticals, Inc. Reports 2Q:15 Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced financial results for the second quarter ended June 30, 2015.

MLV Pounds the Table on BioCryst Pharmaceuticals, Inc.

MLV analyst Vernon Bernardino was out pounding the table on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), reiterating a Buy rating and price target of $15, which represents a …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts